Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Electronic prescribing wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Discovery and development of direct thrombin inhibitors wikipedia , lookup
Discovery and development of direct Xa inhibitors wikipedia , lookup
Name /bks_53161_deglins_md_disk/factorixhuman 02/12/2014 03:10PM Plate # 0-Composite pg 1 # 1 1 Use Cautiously in: Postoperative period (increased risk of thrombosis). factor ix (human) Adverse Reactions/Side Effects CNS: drowsiness, headache, lethargy. CV: changes in BP, changes in heart rate. GI: nausea, vomiting. Derm: flushing, urticaria. Hemat: disseminated intravascular coagulation, thrombosis. Neuro: tingling. Resp: dyspnea. Misc: chills, fever, risk AlphaNine SD, BenFix, Mononine, Profilnine SD, Proplex T, Bebulin VH Classification Therapeutic: hemostatic agents Pharmacologic: blood products, clotting factor replacements Pregnancy Category C Indications Treatment of active or impending bleeding due to factor IX deficiency (hemophilia B, Christmas disease). Treatment of bleeding in patients with factor VIII inhibitors (Proplex T only). Prevention and treatment of bleeding in patients with factor VII deficiency (Proplex T only). Action Factor IX complex preparations (Bebulin VH, Profilnine SD, Proplex T) contain blood coagulation factors II, VII, IX, and X. Purified protein preparations (AlphaNine SD, Benefix, Mononine) contain factor IX activity only. Benefix is made via recombinant DNA technology. Therapeutic Effects: Replacement of deficient factor IX in hemophilia B. Restoration of hemostasis. Pharmacokinetics Absorption: Administered IV only, resulting in complete bioavailability. Distribution: Unknown. Metabolism and Excretion: Rapidly cleared from plasma by utilization in clotting process. Half-life: Factor IX— 24– 32 hr; factor VII— 3– 6 hr. TIME/ACTION PROFILE (hemostasis) ONSET PEAK DURATION IV immediate 10–30 min 1–2 days Contraindications/Precautions Contraindicated in: Factor VII deficiency (except Proplex T); Intravascular coagulation or fibrinolysis associated with liver disease; Allergy to mouse protein (Mononine). ⫽ Genetic Implication. Interactions Drug-Drug: Use with aminocaproic acid mayqrisk of thrombosis. Route/Dosage The following general formula may be used: Human-derived products— Dose (units) ⫽ body weight (kg) ⫻ 1 unit/kg ⫻ desired factor IX increase (% of normal). Recombinant DNA product— Dose (units) ⫽ body weight (kg) ⫻ 1.2 units/kg ⫻ desired factor IX increase (% of normal). Hemophilia B IV (Adults and Children): Major bleeding— 50– 100% activity q 12– 24 hr for 7– 10 days; moderate bleeding— 25– 50% activity q 12– 24 hr until bleeding stops and healing begins (2– 7 days); minor bleeding— 20– 30% activity q 12– 24 hr for 1– 2 days. Factor VII Deficiency(Proplex Tonly) IV (Adults and Children): 75 units/kg. NURSING IMPLICATIONS Assessment ● Monitor BP, pulse, and respirations frequently. ● Obtain history of current trauma; estimate amount of blood loss. ● Monitor for renewed or increased bleeding every 15– 30 min. Immobilize and ap- ROUTE ⫽ Canadian drug name. of transmission of viral hepatitis, risk of transmission of HIV virus, hypersensitivity reactions. ply ice to affected joints. ● If hypersensitivity reaction (fever, chills, tingling, headache, urticaria, changes in BP or pulse, nausea and vomiting, lethargy) occurs, slow infusion and notify physician. Pyrogenic reactions (fever, chills) may also occur and are more common with high doses. ● Lab Test Considerations: Monitor coagulation studies (activated partial thromboplastin time [aPTT], plasma fibrinogen, platelet count, PT, factor IX CAPITALS indicate life-threatening, underlines indicate most frequent. Strikethrough ⫽ Discontinued. PDF Page #1 Name /bks_53161_deglins_md_disk/factorixhuman 02/12/2014 03:10PM Plate # 0-Composite pg 2 # 2 ● Caution patient to avoid products containing aspirin or NSAIDs, because they may 2 further impair clotting. plasma concentrations) before, during, and after therapy to assess effectiveness of therapy. ● Review with patient methods of preventing bleeding (use soft toothbrush, avoid IM Ineffective tissue perfusion (Indications) Risk for injury (Indications) Deficient knowledge, related to medication regimen (Patient/Family Teaching) and subcutaneous injections, avoid potentially traumatic activities). ● Advise patient that the risk of hepatitis or AIDS transmission may be decreased by use of heat-treated preparations. Current screening programs and vaccination with hepatitis B vaccine should help decrease the risk. ● Reinforce need for patients with hemophilia to receive close medical supervision. Implementation Evaluation/Desired Outcomes Potential Nursing Diagnoses ● Dose varies with degree of clotting factor deficit, desired level of clotting factors, ● Prevention of spontaneous bleeding or cessation of bleeding in patients with factor and weight. ● Obtain type and crossmatch of blood in case a transfusion is necessary. ● Hepatitis B vaccine may be given prior to therapy to prevent hepatitis. ● Inform all personnel of patient’s bleeding tendency, to prevent further trauma. Apply pressure to all venipuncture sites for at least 5 min; avoid all IM injections. IX deficiency (hemophilia B, Christmas disease), factor VIII inhibitors, factor VII deficiency, or anticoagulant overdose. Why was this drug prescribed for your patient? IV Administration ● Direct IV: Diluent: Refrigerate concentrate until just prior to reconstitution. Warm diluent (sterile water for injection) to room temperature before reconstituting. Use plastic syringe for preparation and administration. Use the filter needle provided by the manufacturer as an air vent to the vial when reconstituting. After adding diluent, rotate vial gently until contents are completely dissolved. Reconstitution generally requires 5– 10 min for factor IX complex and 1– 5 min for coagulation factor IX. Do not administer solutions that are discolored or contain particulate matter. Do not refrigerate after reconstitution. Begin administration within 3 hr. ● Dry concentrates should be refrigerated; however, do not refrigerate after reconstitution. ● Discard partially used vials. Rate: Rate of administration should be individualized according to specific product and response of the patient. Rates of 100– 200 units/min or 2– 3 mL/min are suggested. Temporarily stop infusion and resume at slower rate if headache, flushing, or changes in pulse or BP occur. ● Additive Incompatibility: Reconstitute only with diluent provided. Administer through a separate line. Do not mix with other solutions or medications. Patient/Family Teaching ● Instruct patient to notify health care professional immediately if bleeding recurs. ● Advise patient to carry identification describing disease process at all times. 䉷 2015 F.A. Davis Company PDF Page #2